ESC 365 - Impact of evolocumab, a PCSK9 inhibitor, withdrawing from regular ldl-apheresis therapy in patients with heterozygous familial hypercholesterolemia.

ESC Premium Access

Impact of evolocumab, a PCSK9 inhibitor, withdrawing from regular ldl-apheresis therapy in patients with heterozygous familial hypercholesterolemia.

Session: Poster session 7 - Lipids

Topic: Lipids (Epidemiology and Prevention)

Speaker: Doctor M. Kawashiri (Kanazawa, JP)

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Doctor Masa-Aki Kawashiri

Kanazawa University Graduate School of Medicine, Kanazawa (Japan)

0 follower

14 more presentations in this session

Impact of the european and american guidelines on the management and treatment of dyslipidemia in a spanish working population

Speaker: Doctor C. Brotons (Barcelona, ES)

Management of hypercholesterolaemia in non-Western countries and achievement of LDL-C goals: an international, cross-sectional, observational study

Speaker: Professor N. Danchin (Paris, FR)

Lipid goals are poorly attained in majority of patients with familial hypercholesterolemia in Latvia at the time of inclusion in the national registry

Speaker: Professor G. Latkovskis (Riga, LV)

The metabolism of triglyceride-rich lipoproteins is impaired in patients with obstructive sleep apnoea: effects of treatment with continuous positive airway pressure.

Speaker: Associate Professor L. Drager (Sao Paulo, BR)

Clinical characteristics and cardiovascular outcomes in subjects who developed acute myocardial infarction despite statin therapy.

Speaker: Doctor K. Tsuda (Takatsuki, JP)

Access the full session

Poster session 7 - Lipids

Speakers: Doctor M. Kawashiri, Doctor C. Brotons, Professor N. Danchin, Professor G. Latkovskis, Associate Professor L. Drager...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources